Brain tumor

Global Brain Tumor Diagnosis & Treatment Market Could Exceed $880 Million By 2027

Retrieved on: 
Tuesday, June 29, 2021
Brain tumor, Cancer, Pediatric cancers, Health, Clinical medicine, Oncology, Anatomical pathology

According to the National Brain Tumor Society, there are around 700,000 Americans living with primary brain cancer, and approximately 84,170 people are estimated to receive a primary brain tumor diagnosis in 2021.

Key Points: 
  • According to the National Brain Tumor Society, there are around 700,000 Americans living with primary brain cancer, and approximately 84,170 people are estimated to receive a primary brain tumor diagnosis in 2021.
  • Reports show that 2 markets in the brain tumor segment: The Brain Tumor Diagnostics and the Brain Tumor Drugs markets.
  • While a report from Fortune Business Insights added that: "The global brain tumor drugs market size was USD 2.35 billion in 2020.
  • The ResearchAndMarket report continued: "The U.S. Market is Estimated at $145.3 Million, While China is Forecast to Grow at 11.2% CAGR The Brain Tumor Diagnosis and Treatment market in the U.S. is estimated at US$145.3 Million in the year 2020.

Global Brain Tumor Diagnosis & Treatment Market Could Exceed $880 Million By 2027

Retrieved on: 
Tuesday, June 29, 2021
Brain tumor, Cancer, Pediatric cancers, Health, Clinical medicine, Oncology, Anatomical pathology

According to the National Brain Tumor Society, there are around 700,000 Americans living with primary brain cancer, and approximately 84,170 people are estimated to receive a primary brain tumor diagnosis in 2021.

Key Points: 
  • According to the National Brain Tumor Society, there are around 700,000 Americans living with primary brain cancer, and approximately 84,170 people are estimated to receive a primary brain tumor diagnosis in 2021.
  • Reports show that 2 markets in the brain tumor segment: The Brain Tumor Diagnostics and the Brain Tumor Drugs markets.
  • While a report from Fortune Business Insights added that: "The global brain tumor drugs market size was USD 2.35 billion in 2020.
  • The ResearchAndMarket report continued: "The U.S. Market is Estimated at $145.3 Million, While China is Forecast to Grow at 11.2% CAGR The Brain Tumor Diagnosis and Treatment market in the U.S. is estimated at US$145.3 Million in the year 2020.

Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027

Retrieved on: 
Tuesday, June 29, 2021
Cancer, Brain tumor, Health, Clinical medicine, Glioblastoma, Blastoma, Glioma, GBM, Glioblast, Zotiraciclib

The report said that: " The global Glioblastoma multiforme(GBM) drugs market is projected to reach nearly $1.8 billion by 2027, expanding at a CAGR of 12.8% during the forecast period, driven by rising geriatric population, growing incidence cases and rich clinical pipeline of new products.

Key Points: 
  • The report said that: " The global Glioblastoma multiforme(GBM) drugs market is projected to reach nearly $1.8 billion by 2027, expanding at a CAGR of 12.8% during the forecast period, driven by rising geriatric population, growing incidence cases and rich clinical pipeline of new products.
  • Glioblastoma is the most common primary malignant form of brain cancer.Despite technological advances in surgery and radio-chemotherapy, glioblastoma remains largely resistant to treatment."
  • The iHealthcareAnaylist report continued: "A few agents have been approved by the US FDA for the treatment of high-grade gliomas following orphan drug designation, but most have failed to reach the market.
  • CNS recently announced the start of patient enrollment in its potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme.

Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027

Retrieved on: 
Tuesday, June 29, 2021
Cancer, Brain tumor, Health, Clinical medicine, Glioblastoma, Blastoma, Glioma, GBM, Glioblast, Zotiraciclib

The report said that: " The global Glioblastoma multiforme(GBM) drugs market is projected to reach nearly $1.8 billion by 2027, expanding at a CAGR of 12.8% during the forecast period, driven by rising geriatric population, growing incidence cases and rich clinical pipeline of new products.

Key Points: 
  • The report said that: " The global Glioblastoma multiforme(GBM) drugs market is projected to reach nearly $1.8 billion by 2027, expanding at a CAGR of 12.8% during the forecast period, driven by rising geriatric population, growing incidence cases and rich clinical pipeline of new products.
  • Glioblastoma is the most common primary malignant form of brain cancer.Despite technological advances in surgery and radio-chemotherapy, glioblastoma remains largely resistant to treatment."
  • The iHealthcareAnaylist report continued: "A few agents have been approved by the US FDA for the treatment of high-grade gliomas following orphan drug designation, but most have failed to reach the market.
  • CNS recently announced the start of patient enrollment in its potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme.

FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme

Retrieved on: 
Tuesday, June 29, 2021
Cancer, Clinical medicine, Health, Oncology, Brain tumor, Glioblastoma, Blastoma, Zotiraciclib, Medivir

As previously reported, the Company has also received Orphan Drug Designation from the FDA for Berubicin for the treatment of patients with recurrent GBM.

Key Points: 
  • As previously reported, the Company has also received Orphan Drug Designation from the FDA for Berubicin for the treatment of patients with recurrent GBM.
  • "Receiving Fast Track Designation from the U.S. FDA is a huge achievement in our advancement of Berubicin for the treatment of glioblastoma, the most aggressive, deadly and treatment-resistant type of cancer that forms in the brain.
  • CNS recently announced the start of patient enrollment in its potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme.
  • CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas.

Anova Partners With NeOnc Technologies To Bring NEO100 to Patients With IDH1 Mutated Gliomas

Retrieved on: 
Tuesday, June 29, 2021
Health, Technology, Software, Clinical trials, Pharmaceutical, Biotechnology, Design of experiments, Health sciences, Brain tumor, Health, IDH1, Glioma, Clinical research, Drug discovery, Pharmaceutical industry, Analysis of variance, Clinical trial

Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating promising treatments to market with its transformative AnovaOS technology platform, and the industrys first collaborative learning system, today announced a partnership with the NeOnc Technologies, Inc. (NeOnc) to accelerate the development of NEO100 for patients with IDH1 mutated gliomas.

Key Points: 
  • Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating promising treatments to market with its transformative AnovaOS technology platform, and the industrys first collaborative learning system, today announced a partnership with the NeOnc Technologies, Inc. (NeOnc) to accelerate the development of NEO100 for patients with IDH1 mutated gliomas.
  • NeOnc is a developer of a novel molecular technology that provides enhanced targeted delivery of therapeutics for the treatment of CNS-based diseases.
  • As part of the partnership, Anova will support patient identification and access to NEO100 clinical trials, and when clinical trials are not an option for patients with IDH1 mutated Glioma, early access for compassionate use will be supported.
  • We look forward to working with Anova, and helping to accelerate development efforts of NEO100.

Looking at Tumors Through a New Lens: New Research May Improve Efficacy of Glioblastoma Immunotherapy

Retrieved on: 
Tuesday, June 29, 2021
Cancer, Health, Medicine, Oncology, Melanoma, Glioblastoma, Vaccines, Cancer stem cell, Brain tumor

To improve the treatment efficacy, researchers are looking for vulnerabilities in surgically removed glioblastoma tissues, but this has been difficult due to the vast differences within the tumor and between patients.

Key Points: 
  • To improve the treatment efficacy, researchers are looking for vulnerabilities in surgically removed glioblastoma tissues, but this has been difficult due to the vast differences within the tumor and between patients.
  • To address this challenge, researchers at Institute for Systems Biology (ISB) and their collaborators developed a new way to study tumors.
  • The method builds mathematical models using machine learning-based image analysis and multiplex spatial protein profiling of microscopic compartments in the tumor.
  • Using melanoma to guide the interpretation of glioblastoma analyses, they identified the proteins that correlate with tumor-killing T cells, tumor growth, and immune cell-cell interactions.

WPD Pharmaceuticals Plans to Commence Phase Ib/II Study of Berubicin for the Treatment of Glioblastoma in 2H 2021

Retrieved on: 
Monday, June 28, 2021
Health sciences, Health, Brain tumor, Medicine, Clinical trial, Glioma

WPD is planning the Phase I clinical trial for malignant gliomas at two clinical sites in Poland.

Key Points: 
  • WPD is planning the Phase I clinical trial for malignant gliomas at two clinical sites in Poland.
  • The study includes a multicenter, open-label, dose escalation Phase I study of intravenous Berubicin in pediatric patients.
  • This Phase I trial of Berubicin represents the first ever investigation of Berubicin in pediatric brain tumors.
  • The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes for most compounds 30 countries in Europe and Asia, including Russia.

Global Brain Tumor Drugs Market Report 2021-2025 & Long-term Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 23, 2021
Pharmaceutical, Health, Oncology, Life sciences, Companies, Health sciences, Bayer, Kenilworth, New Jersey, Merck & Co., Schering-Plough, Pfizer, Brain tumor, Human brain, Oxford–AstraZeneca COVID-19 vaccine, AstraZeneca

The "Brain Tumor Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Brain Tumor Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the brain tumor drugs market are Pfizer Inc., Shimadzu Corporation, Toshiba Medical Systems, Merck & Co. Inc., and AstraZeneca.
  • The brain tumor drugs market consists of sales of drugs which are used to cure a mass growth of abnormal cells in the human brain.
  • Global Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Brain Tumor Diagnosis and Treatment Research Report 2021 - Global Market Trajectory & Analytics, 2012-2019 & 2020-2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 23, 2021
Health, Oncology, Brain tumor, Compound annual growth rate

The "Brain Tumor Diagnosis and Treatment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Brain Tumor Diagnosis and Treatment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Brain Tumor Diagnosis and Treatment estimated at US$537.5 Million in the year 2020, is projected to reach a revised size of US$887.5 Million by 2027, growing at a CAGR of 7.4% over the period 2020-2027.
  • Primary Brain Tumor, one of the segments analyzed in the report, is projected to record 7.2% CAGR and reach US$587.1 Million by the end of the analysis period.
  • The U.S. Market is Estimated at $145.3 Million, While China is Forecast to Grow at 11.2% CAGR
    The Brain Tumor Diagnosis and Treatment market in the U.S. is estimated at US$145.3 Million in the year 2020.